PerkinElmer Partners withSofie Biosciences to Deliver Benchtop PET In Vivo Imaging Systems to Preclinical Research Professionals
WALTHAM, MA, UNITED STATES - June 6, 2014 - Preclinical PET Imaging Instrumentsin Benchtop Format Help Support High Performance Disease Research, Drug Discovery and Clinical Translational Applications
WHAT: PerkinElmer Inc., a global leader focused on the health and safety of people and the environment, andSofie Biosciences, a leader in the field of PET imaging, today announced an agreementin which PerkinElmer will exclusively commercialize and sell preclinical Positron Emission Tomography (PET)– X-Ray and 3-dimensional Computed Tomography (CT) imaging systems developed by,or in conjunction with,Sofie Biosciences.
PET imaging is an essential preclinical research tool in understanding the biology of disease, biological impact of drugs, and clinical translation. PerkinElmer will work together with Sofie on the manufacturing and development of thesenew imaging instrument systems and assist Sofie inmarketing Sofie’s chemical synthesis and advanced probe development capabilities.
These benchtopPET imagingsystemsprovide highly sensitiveand quantitative biological assays for application data insuch fields as oncology, immunology, neurobiology, cardiology, and pharmacology. These systems are complementary to PerkinElmer’s current portfolio of preclinical offerings, which includes IVIS®optical imaging systems (available with integrated x-ray or CT,), high-performance dedicated Quantum™ microCT systems and a full line of imaging reagents and probes, including PET radioisotopes.
In addition to the current G4 PET/XRay system, PerkinElmer and Sofie are announcing a new translational imaging solution, the G8 PET/CT Small Animal Imaging System. This offering integratesPETand CTintoan innovative, high-performance benchtop systembuilt to enable preclinical workflows for biologists, biochemists, and pharmacologists.
“As a leading provider of imaging platforms for cellular, tissue and in vivoresearch,PerkinElmer is pleased to partnerwith Sofie, a leader in the field of PET imaging, todeliver these systems to the globalpreclinical research community,”said Brian Kim, President, Life Sciences & Technology, PerkinElmer. “In vivopreclinical imaging plays an integral role in translational research and drug discovery, facilitatinga unique understanding of disease initiation, progression and therapeutic responses.”
“Our relationship combines PerkinElmer’s preclinical leadership with Sofie’s PET expertise to bring new translational imaging solutions to the global research community,” said Patrick Phelps, President and CEO of Sofie Biosciences.
AT SNMMI
2014: PerkinElmer will showcase theG8PET/CT system at Booth #1235at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2014 conference June 7-11 in St. Louis, Missouri. Sofie will displaythe G8 PET/CT and G4 PET/X Ray systems, along with its chemistry product, at Booth #901.
MORE: For more information on theG8PET/CT or G4 PET/X-RAYsystems, please visitwww.perkinelmer.com/Catalog/Category/ID/PET-Imaging-Systems
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.2 billion in 2013, has about 7,600 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
About Sofie Biosciences
Sofie is combining new PET imaging agents with innovative imaging and synthesis systems to provide researchers and physicians with tools to better investigate the biology of disease. By empowering a wide array of people with valuable, translational imaging tools, Sofie is making PET scans more accessible and increasing the diversity of its applications.
Media Contacts:PerkinElmer
Ilene Schneider
[email protected]
+1 (949) 433-6862
Sofie Biosciences
Philipp Czernin